WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

Kun Yang^1,2,3, Shilong Chang¹, Yucheng Wang¹, Minghui Wang¹, Jiahui Yang¹, Shuang Liu^1,2,3, Kun Liu^1,2,3, Linyan Xue^1,2,3,*

CMC-Computers, Materials & Continua, Vol.78, No.1, pp. 393-410, 2024, DOI:10.32604/cmc.2023.044994 - 30 January 2024

Abstract Clear cell renal cell carcinoma (ccRCC) represents the most frequent form of renal cell carcinoma (RCC), and accurate International Society of Urological Pathology (ISUP) grading is crucial for prognosis and treatment selection. This study presents a new deep network called Multi-scale Fusion Network (MsfNet), which aims to enhance the automatic ISUP grade of ccRCC with digital histopathology pathology images. The MsfNet overcomes the limitations of traditional ResNet50 by multi-scale information fusion and dynamic allocation of channel quantity. The model was trained and tested using 90 Hematoxylin and Eosin (H&E) stained whole slide images (WSIs), which… More >

RENLONG ZHOU^1,2,#, SHUANG LI^3,#, XILIN XIAO^1,*

BIOCELL, Vol.47, No.11, pp. 2397-2408, 2023, DOI:10.32604/biocell.2023.030281 - 27 November 2023

Abstract Background: In many cancer types, aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been found to be associated with tumor cell proliferation and prognosis. However, the role of ARNT2 in clear cell renal cell carcinoma (ccRCC) has not been completely elucidated. In this study, the potential role of ARNT2 in ccRCC development was characterized. Methods: A pan-cancer dataset (TCGA-TARGET-GTEx) was accessed from UCSC Xena Data Browser. ARNT2 expression in normal and tumor samples was compared. Univariate Cox regression was performed to evaluate the prognostic value of ARNT2. Single sample gene set enrichment analysis (ssGSEA) was… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

WEI BAO^1,#, QIANGUANG HAN^2,#, XIAO GUAN³, ZIJIE WANG², MIN GU^1,2,*

Oncology Research, Vol.31, No.2, pp. 181-192, 2023, DOI:10.32604/or.2023.028051 - 10 April 2023

Abstract Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk… More >

Yanwen Lu^1,#, Wenliang Ma^1,#, Xiang Dong^1,#, Mackenzie Brown², Tong Lu^3,*, Weidong Gan^1,*

CMES-Computer Modeling in Engineering & Sciences, Vol.136, No.1, pp. 347-362, 2023, DOI:10.32604/cmes.2023.024909 - 05 January 2023

Abstract This study aims to apply ResNet-18 convolutional neural network (CNN) and XGBoost to preoperative computed tomography (CT) images and clinical data for distinguishing Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) from common subtypes of renal cell carcinoma (RCC) in order to provide patients with individualized treatment plans. Data from 45 patients with Xp11.2 tRCC from January 2007 to December 2021 are collected. Clear cell RCC (ccRCC), papillary RCC (pRCC), or chromophobe RCC (chRCC) can be detected from each patient. CT images are acquired in the following three phases: unenhanced, corticomedullary, and nephrographic. A unified framework More >

ZEKUN XIN^1,#, YUDAN MA^2,#, WEIQIANG SONG³, HAO GAO³, LIJUN DONG³, BAO ZHANG^1,*, ZHILONG REN^3,*

BIOCELL, Vol.47, No.3, pp. 555-567, 2023, DOI:10.32604/biocell.2023.026254 - 03 January 2023

Abstract Background: Recently, researchers have been attracted in identifying the crucial genes related to cancer, which plays important role in cancer diagnosis and treatment. However, in performing the cancer molecular subtype classification task from cancer gene expression data, it is challenging to obtain those significant genes due to the high dimensionality and high noise of data. Moreover, the existing methods always suffer from some issues such as premature convergence. Methods: To address those problems, we propose a new ant colony optimization (ACO) algorithm called DACO to classify the cancer gene expression datasets, identifying the essential genes of… More >

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838 - 29 June 2022

Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

GIUSEPPE STEFANO NETTI^1,*, FEDERICA SPADACCINO¹, VALERIA CATALANO¹, GIUSEPPE CASTELLANO², GIOVANNI STALLONE³, ELENA RANIERI¹

BIOCELL, Vol.46, No.10, pp. 2235-2239, 2022, DOI:10.32604/biocell.2022.020209 - 13 June 2022

Abstract Pentraxin-3 (PTX3), the prototype of long pentraxins, seems to influence complement system (CS) modulation. PTX3 and CS sustain carcinogenesis, enriching tumor microenvironment (TME) with pro-inflammatory molecules promoting angiogenesis in prostate cancer (PC) and renal cell carcinoma (RCC). Furthermore, cancer cells overexpress complement regulatory proteins, such as CD46, CD55 and CD59, which negatively affect complement pathways for support cancer cells survival. This viewpoint aims to elucidate the ambivalent role of PTX3 and the CS in the context of tumor microenvironment (TME). More >